GREY:ATBPF - Post by User
Post by
ace1mccoyon Jun 18, 2021 8:42am
462 Views
Post# 33410164
RJ Initates Coverage... G&M
RJ Initates Coverage... G&M * Raymond James analyst David Novak initiated coverage of Antibe Therapeutics Inc. (ATE-T) with an “outperform” rating and $7 target. The current average is $17.59.
“We believe ATE shares are well-positioned for a significant market re-rating over the next 12-months and thus view the company as an attractive investment opportunity for risk-tolerant investors,” he said.